

Regimen Reference Order – GENU – mitoXANTRONE + predniSONE (MP)

ARIA: GENU – [MP]

Planned Course: Every 21 days for 10 cycles
Indication for Use: Prostate Cancer; Metastatic; Castration-Resistant
CVAD: At Provider’s Discretion

Proceed with treatment if:
ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$
 ❖ Contact Physician if parameters not met
Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements		
Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GENU – mitoXANTRONE + prednisone (MP)		
Establish primary solution 500 mL of: normal saline		
Drug	Dose	CCMB Administration Guideline
Days 1 to 21		
predniSONE	10 mg	Orally once daily in the morning with food (Self-administered at home)
Day 1		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
mitoXANTRONE	12 mg/m^2	IV in normal saline 50 mL over 5 minutes

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

- Hepatitis B serology
- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)
- Cardiac Monitoring
- Left Ventricular Ejection Fraction (LVEF) and EKG monitoring is recommended at baseline and as clinically indicated
- All Cycles
- CBC and biochemistry as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- predniSONE is a cancer therapy in this treatment regimen. Remind patient to take predniSONE at home
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- mitoXANTRONE is cardiotoxic
- mitoXANTRONE may cause hyperuricemia
- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy **Hepatitis B Monitoring for Oncology and Hematology Patients** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis